InspireMD, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report; the provided text does not give separate Q4 financial results. Amounts below are in U.S. dollars unless stated otherwise.
Business context
InspireMD develops and commercializes stents using its proprietary MicroNet embolic-protection mesh. Its main commercial product is CGuard EPS for carotid artery disease, sold internationally; MGuard Prime is a bare-metal coronary stent. The company stated that none of its products could then be marketed in the United States. Its strategy centers on expanding CGuard sales and pursuing U.S. regulatory approval, while other product development is constrained by resources.
Financial performance and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $2.485 million | $3.721 million | Down $1.236 million, or 33.2% |
| Gross profit / margin | $0.083 million / 3.3% | $0.756 million / 20.3% | Gross profit down 89.0% |
| Operating expenses | $10.463 million | $10.572 million | Down $0.109 million |
| Operating loss | $10.380 million | $9.816 million | Loss increased |
| Net loss | $10.544 million | $10.040 million | Loss increased $0.504 million, or 5.0% |
| Net loss per share, basic and diluted | $0.46 | $4.80 | Weighted-average shares increased substantially |
| Cash used in operating activities | $9.081 million | $9.810 million | Use decreased $0.729 million |
Revenue declined mainly because COVID-19 postponed elective procedures and because the $580,000 Bosti distributor settlement was charged against revenue. CGuard sales were $2.764 million versus $3.265 million in 2019; management reported MGuard sales of $301,000 versus $456,000 before the settlement. The financial-statement product table instead presents MGuard revenue net of the settlement, at negative $279,000, making that presentation important to reconcile.
At year-end, cash and cash equivalents were $12.645 million, up from $5.514 million. Working capital was $11.634 million and current assets were 4.1 times current liabilities. Total liabilities were $5.614 million, including $1.399 million of operating lease liabilities; the filing does not report conventional borrowings or debt. The company reported an accumulated deficit of $168.176 million. Management said available resources could fund planned operations for at least 12 months from issuance of the financial statements, but expected ongoing losses and negative operating cash flow and said additional funding may be needed.
Material changes and notable items
- Gross margin fell sharply, reflecting the distributor settlement and lower product sales, partly offset by lower facility-upgrade and miscellaneous costs.
- Research and development expense declined 24.4% to $2.233 million, mainly as IDE-related clinical costs and certain prior-year expenses decreased; investment in CGuard delivery-system and accessory development increased.
- Selling and marketing expense declined 12.2% to $2.103 million, largely due to lower travel and promotional costs. General and administrative expense rose 17.3% to $6.127 million, including a $400,000 prior-underwriter settlement charge and higher insurance and regulatory costs.
- Financing activities provided $16.395 million in 2020, including proceeds from the June public offering, warrant exercises and ATM sales. Cash flow remained dependent on financing despite lower operating cash use.
- After year-end, the company reported approximately $18.9 million net proceeds from its February 2021 public offering, $5.659 million gross from additional ATM sales, $0.9 million from a Chinese partner investment, and approximately $9.469 million from Series F and G warrant exercises. These transactions and related warrant issuances increased the share count and potential dilution. The filing reports 117,832,226 common shares outstanding as of March 8, 2021.
- The Bosti litigation was resolved for $580,000, paid January 25, 2021 and recorded as a reduction of 2020 revenue. A separate 2020 settlement with a former underwriter cost $400,000 in cash and included repricing warrants.
Outlook, risks and contingencies
The FDA approved an IDE for the CARENET-III pivotal CGuard study in September 2020. The planned study is expected to enroll approximately 315 patients; IDE approval permits the study to proceed but is not FDA approval to market the product. The filing provides no specific revenue, earnings or margin guidance. Management expected sales fluctuations to continue while COVID-19 affected elective procedures and said timing of recovery was uncertain.
Key risks include continued losses and need for capital; dilution from equity and warrants; clinical-trial enrollment, outcomes and regulatory delays; dependence on international sales and distributors; reimbursement and market adoption; competition, particularly the shift to drug-eluting coronary stents; reliance on a single Israeli manufacturing facility and certain suppliers; and COVID-19, currency, geopolitical and regulatory risks. CGuard’s European CE-mark certification transition to the EU Medical Device Regulation is also a compliance risk. The company regained NYSE American listing compliance in August 2020 but disclosed that continued compliance is not assured.
The independent auditor issued an unqualified opinion on the consolidated financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2020; the auditor was not engaged to opine on internal control effectiveness.
Most important facts for investors to verify
- Reconcile reported revenue and product sales, especially the $580,000 settlement and the differing MGuard presentations.
- Assess the company’s cash runway against its $9.081 million annual operating cash use, and confirm the timing and net proceeds of post-year-end financings and warrant exercises.
- Review fully diluted share exposure, including Series G and other outstanding warrants, preferred-stock conversions, and equity awards.
- Track CARENET-III site activation, enrollment, endpoints and costs, and distinguish IDE authorization from commercial FDA clearance or approval.
- Monitor elective-procedure recovery, CGuard adoption, gross-margin improvement, supplier continuity and European MDR compliance.